Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) in prostate cancer: An J, Sun Y-P, Adams J, Fisher M, Belldegrun A, Rettig MB, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA [J An, Y-PS, MF, MBR]; Millennium Pharmaceuticals, Inc., Cambridge, MA [J Adams]; and University of California at Los Angeles School of Medicine, Los Angeles, CA [AB, MBR]. Clinical Cancer Research 2003;9:4537–4545